Alexander Stein

Universität Hamburg — Germany

Medicine · Health Sciences

38h-index7.5kcitations338works5.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Colorectal Cancer Treatments and Studies(113), Gastric Cancer Management and Outcomes(77), Cancer Immunotherapy and Biomarkers(43), Cancer Treatment and Pharmacology(40), Genetic factors in colorectal cancer(26)

Publications337 total

Brain-derived synaptic vesicles have an intrinsic ability to sequester tubulin
BMC Biology·2025Open Access
Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial
The Lancet·2025· 12 citedOpen Access
Perioperative pembrolizumab, trastuzumab and FLOT in HER2-positive localized esophagogastric adenocarcinoma: a phase 2 trial
Nature Medicine·2025· 4 citedOpen Access
LBA30 Zanzalintinib plus atezolizumab (zanza + atezo) vs regorafenib (rego) in patients (pts) with previously treated metastatic colorectal cancer (mCRC): Primary overall survival (OS) analysis from the randomized, open-label, phase III STELLAR-303 study
Annals of Oncology·2025Open Access
2095MO Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive localized esophagogastric adenocarcinoma: Interim analysis of the phase II PHERFLOT/IKF-053 trial of the AIO study group (AIO STO 0321)
Annals of Oncology·2025
Korrelation von Gesamtüberleben und RECIST-definiertem Ansprechen bei Patienten mit soliden Tumoren und Therapie mit Immuncheckpoint-Inhibitoren – Gepoolte Analyse der RAMONA, INTEGA, OPTIM, ELDORANDO, FORCE, TITAN-RCC und TITAN-TCC Studien der AiO Studiengruppe
Zeitschrift für Gastroenterologie·2025Open Access
FOLFOXIRI/bevacizumab versus doublets/bevacizumab as initial therapy of unresectable liver-only, right-sided and/or RAS or BRAF mutated metastatic colorectal cancer: An individual patient data-based pooled analysis of randomized trials
European Journal of Cancer·2025· 2 cited
Inflammation and limited adaptive immunity predict worse outcomes on immunotherapy in head and neck cancer
npj Precision Oncology·2025· 4 citedOpen Access
407P Immune composition-based efficacy assessment of first-line immune-chemotherapy combinations in gastroesophageal cancer: Subgroup analysis of the phase II IKF-AIO-STO-0417 / moonlight trial
Annals of Oncology·2025Open Access
481P The predictive role of neutrophil-to-lymphocyte ratio in patients with solid cancers treated with immune checkpoint inhibitors: A pooled analysis of seven clinical trials of the German AIO study group
Annals of Oncology·2025Open Access
Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer
New England Journal of Medicine·2025· 135 cited
Author Correction: Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer
Nature·2025· 1 citedOpen Access
Brain-derived synaptic vesicles have an intrinsic ability to sequester tubulin
2025Open Access
UV1 vaccination in pembrolizumab-treated patients with recurrent or metastatic head and neck cancer: A randomized multicenter phase 2 trial
Med·2025· 4 citedOpen Access
Data from Inflammatory Stress Determines the Need for Chemotherapy in Patients with HER2-Positive Esophagogastric Adenocarcinoma Receiving Targeted Therapy and Immunotherapy
2025Open Access
Supplementary Tables 1-3 from Inflammatory Stress Determines the Need for Chemotherapy in Patients with HER2-Positive Esophagogastric Adenocarcinoma Receiving Targeted Therapy and Immunotherapy
2025Open Access
Supplementary Figure 4 from Inflammatory Stress Determines the Need for Chemotherapy in Patients with HER2-Positive Esophagogastric Adenocarcinoma Receiving Targeted Therapy and Immunotherapy
2025Open Access
Supplementary Figure 3 from Inflammatory Stress Determines the Need for Chemotherapy in Patients with HER2-Positive Esophagogastric Adenocarcinoma Receiving Targeted Therapy and Immunotherapy
2025Open Access
Supplementary Figure 2 from Inflammatory Stress Determines the Need for Chemotherapy in Patients with HER2-Positive Esophagogastric Adenocarcinoma Receiving Targeted Therapy and Immunotherapy
2025Open Access
Supplementary Figure 1 from Inflammatory Stress Determines the Need for Chemotherapy in Patients with HER2-Positive Esophagogastric Adenocarcinoma Receiving Targeted Therapy and Immunotherapy
2025Open Access
page 1 of 17Next →

Frequent Co-authors

Carsten Bokemeyer(12), Hans‐Joachim Schmoll(7), Mascha Binder(7), Dirk Arnold(6), Zev A. Wainberg(6), Eray Goekkurt(6), Vivek Subbiah(5), Joseph Tintelnot(5), Sylvie Lorenzen(5), Thomas J. Ettrich(5), Salah‐Eddin Al‐Batran(5), Axel Hinke(5), Susanna Hegewisch‐Becker(5), Paul Burgess(4), Palanichamy Ilankumaran(4), Jorge Riera‐Knorrenschild(4), Eric Van Cutsem(3), Ulrik Lassen(3), Élena Elez(3), Antoîne Italiano(3)